BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers (Basel) 2019;11:E971. [PMID: 31336704 DOI: 10.3390/cancers11070971] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Orloff M. Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy. Ocul Oncol Pathol 2021;7:168-76. [PMID: 34307327 DOI: 10.1159/000513336] [Reference Citation Analysis]
2 Masaoutis C, Kokkali S, Theocharis S. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment. Expert Opin Investig Drugs 2021;30:555-69. [PMID: 33650931 DOI: 10.1080/13543784.2021.1898587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fine GC, Covington MF, Koppula BR, Salem AE, Wiggins RH, Hoffman JM, Morton KA. PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors. Cancers (Basel) 2022;14:2835. [PMID: 35740501 DOI: 10.3390/cancers14122835] [Reference Citation Analysis]
4 Eleuteri A, Rola AC, Kalirai H, Hussain R, Sacco J, Damato BE, Heimann H, Coupland SE, Taktak AFG. Cost-utility analysis of a decade of liver screening for metastases using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO). Comput Biol Med 2021;130:104221. [PMID: 33516960 DOI: 10.1016/j.compbiomed.2021.104221] [Reference Citation Analysis]
5 Mallone F, Sacchetti M, Lambiase A, Moramarco A. Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma. Cancers (Basel) 2020;12:E2761. [PMID: 32992823 DOI: 10.3390/cancers12102761] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Smit KN, Jager MJ, de Klein A, Kiliҫ E. Uveal melanoma: Towards a molecular understanding. Prog Retin Eye Res 2020;75:100800. [PMID: 31563544 DOI: 10.1016/j.preteyeres.2019.100800] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
7 Hoyek S, Kourie HR, Labaki C, Antoun J. Immune checkpoint inhibitors in ocular melanomas: contrasting efficacy with cutaneous melanomas. Immunotherapy 2020;12:1149-52. [PMID: 33076742 DOI: 10.2217/imt-2020-0234] [Reference Citation Analysis]
8 Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, Carvajal RD, Belfort RN, Jia R, Shields JA, Damato BE. Uveal melanoma. Nat Rev Dis Primers 2020;6:24. [PMID: 32273508 DOI: 10.1038/s41572-020-0158-0] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 34.5] [Reference Citation Analysis]
9 Gajdzis M, Kaczmarek R, Gajdzis P. Novel Prognostic Immunohistochemical Markers in Uveal Melanoma-Literature Review. Cancers (Basel) 2021;13:4031. [PMID: 34439182 DOI: 10.3390/cancers13164031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Voynov V, Adam PJ, Nixon AE, Scheer JM. Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors. Antibodies (Basel) 2020;9:E65. [PMID: 33217946 DOI: 10.3390/antib9040065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Egen JG, Ouyang W, Wu LC. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity 2020;52:36-54. [DOI: 10.1016/j.immuni.2019.12.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 22.5] [Reference Citation Analysis]
12 You G, Won J, Lee Y, Moon D, Park Y, Lee SH, Lee SW. Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines (Basel) 2021;9:724. [PMID: 34358141 DOI: 10.3390/vaccines9070724] [Reference Citation Analysis]
13 Olson DJ, Luke JJ. Improving therapy in metastatic uveal melanoma by understanding prior failures. Oncoscience 2020;7:40-3. [PMID: 32676517 DOI: 10.18632/oncoscience.510] [Reference Citation Analysis]
14 Pereira ACL, Bezerra KS, Santos JLS, I N Oliveira J, Freire VN, Fulco UL. In silico approach of modified melanoma peptides and their immunotherapeutic potential. Phys Chem Chem Phys 2021;23:2836-45. [PMID: 33470998 DOI: 10.1039/d0cp05322h] [Reference Citation Analysis]
15 Toro MD, Gozzo L, Tracia L, Cicciù M, Drago F, Bucolo C, Avitabile T, Rejdak R, Nowomiejska K, Zweifel S, Yousef YA, Nazzal R, Romano GL. New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review. Biomedicines 2021;9:1311. [PMID: 34680428 DOI: 10.3390/biomedicines9101311] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Seedor RS, Eschelman DJ, Gonsalves CF, Adamo RD, Orloff M, Amjad A, Sharpe-Mills E, Chervoneva I, Shields CL, Shields JA, Mastrangelo MJ, Sato T. An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis. Cancers (Basel) 2020;12:E117. [PMID: 31906411 DOI: 10.3390/cancers12010117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
17 Bol KF, Donia M, Heegaard S, Kiilgaard JF, Svane IM. Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. Int J Mol Sci 2020;21:E5231. [PMID: 32718045 DOI: 10.3390/ijms21155231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Roelofsen CDM, Wierenga APA, van Duinen S, Verdijk RM, Bleeker J, Marinkovic M, Luyten GPM, Jager MJ. Five Decades of Enucleations for Uveal Melanoma in One Center: More Tumors with High Risk Factors, No Improvement in Survival over Time. Ocul Oncol Pathol 2021;7:133-41. [PMID: 33981696 DOI: 10.1159/000509918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Nell RJ, Zoutman WH, Calbet-Llopart N, Garcia AP, Menger NV, Versluis M, Puig S, Gruis NA, van der Velden PA. Accurate Quantification of T Cells in Copy Number Stable and Unstable DNA Samples Using Multiplex Digital PCR. J Mol Diagn 2021:S1525-1578(21)00383-4. [PMID: 34775028 DOI: 10.1016/j.jmoldx.2021.10.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Martinez-Perez D, Viñal D, Solares I, Espinosa E, Feliu J. Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. Cancers (Basel) 2021;13:5968. [PMID: 34885078 DOI: 10.3390/cancers13235968] [Reference Citation Analysis]
21 Javed A, Milhem M. Role of Natural Killer Cells in Uveal Melanoma. Cancers (Basel) 2020;12:E3694. [PMID: 33317028 DOI: 10.3390/cancers12123694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Bellone M, Bregni M, Bronte V, Ugel S, Ferrucci PF, Di Nicola M, Nisticò P, Zuccolotto G, Rosato A, Russo V, Sica A, Colombo MP. Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. Cancer Immunol Immunother 2021. [PMID: 34755203 DOI: 10.1007/s00262-021-03104-1] [Reference Citation Analysis]
23 Huang F, Santinon F, Flores González RE, Del Rincón SV. Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy. Front Oncol 2021;11:756001. [PMID: 34604096 DOI: 10.3389/fonc.2021.756001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Fu Y, Xiao W, Mao Y. Recent Advances and Challenges in Uveal Melanoma Immunotherapy. Cancers 2022;14:3094. [DOI: 10.3390/cancers14133094] [Reference Citation Analysis]
25 Bechrakis NE, Bornfeld N, Heindl LM, Skoetz N, Leyvraz S, Joussen AM. Uveal Melanoma - Standardised Procedure in Diagnosis, Therapy and Surveillance. Klin Monbl Augenheilkd 2021;238:761-72. [PMID: 34376006 DOI: 10.1055/a-1534-0198] [Reference Citation Analysis]
26 Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs 2022;14:2014296. [PMID: 35030985 DOI: 10.1080/19420862.2021.2014296] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 31.0] [Reference Citation Analysis]
27 Mak LY, Seto WK, Yuen MF. Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. Viruses 2021;13:1169. [PMID: 34207458 DOI: 10.3390/v13061169] [Reference Citation Analysis]
28 Mehmi I, Hamid O. Immunotherapy of cancer in the era of checkpoint inhibitor. Clin Exp Metastasis 2021. [PMID: 34878618 DOI: 10.1007/s10585-021-10132-9] [Reference Citation Analysis]
29 Xu TT, Moser JC, Dalvin LA. Uveal melanoma: laboratory advances and new frontiers in patient care. Curr Opin Ophthalmol 2021;32:301-8. [PMID: 33606406 DOI: 10.1097/ICU.0000000000000744] [Reference Citation Analysis]
30 Hussain RN, Coupland SE, Kalirai H, Taktak AFG, Eleuteri A, Damato BE, Groenewald C, Heimann H. Small High-Risk Uveal Melanomas Have a Lower Mortality Rate. Cancers (Basel) 2021;13:2267. [PMID: 34066842 DOI: 10.3390/cancers13092267] [Reference Citation Analysis]
31 Fergusson JR, Wallace Z, Connolly MM, Woon AP, Suckling RJ, Hine DW, Barber C, Bunjobpol W, Choi BS, Crespillo S, Dembek M, Dieckmann N, Donoso J, Godinho LF, Grant T, Howe D, McCully ML, Perot C, Sarkar A, Seifert FU, Singh PK, Stegmann KA, Turner B, Verma A, Walker A, Leonard S, Maini MK, Wiederhold K, Dorrell L, Simmons R, Knox A. Immune-Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B-Infected Cells. Hepatology 2020;72:1528-40. [PMID: 32770836 DOI: 10.1002/hep.31503] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
32 Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Caracò C, Thurin M. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med 2020;18:346. [PMID: 32894202 DOI: 10.1186/s12967-020-02482-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Lamas NJ, Martel A, Nahon-Estève S, Goffinet S, Macocco A, Bertolotto C, Lassalle S, Hofman P. Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions. Cancers (Basel) 2021;14:96. [PMID: 35008260 DOI: 10.3390/cancers14010096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Liu AW, Wei AZ, Maniar AB, Carvajal RD. Tebentafusp in Advanced Uveal Melanoma: Proof of Principal for the Efficacy of T-Cell Receptor Therapeutics and Bispecifics in Solid Tumors. Expert Opinion on Biological Therapy. [DOI: 10.1080/14712598.2022.2031970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Ortega MA, Fraile-Martínez O, García-Honduvilla N, Coca S, Álvarez-Mon M, Buján J, Teus MA. Update on uveal melanoma: Translational research from biology to clinical practice (Review). Int J Oncol 2020;57:1262-79. [PMID: 33173970 DOI: 10.3892/ijo.2020.5140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
36 Rossi E, Croce M, Reggiani F, Schinzari G, Ambrosio M, Gangemi R, Tortora G, Pfeffer U, Amaro A. Uveal Melanoma Metastasis. Cancers (Basel) 2021;13:5684. [PMID: 34830841 DOI: 10.3390/cancers13225684] [Reference Citation Analysis]
37 Dhillon S. Tebentafusp: First Approval. Drugs 2022. [PMID: 35364798 DOI: 10.1007/s40265-022-01704-4] [Reference Citation Analysis]
38 Chen TT. Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development. Expert Opin Biol Ther 2022. [PMID: 35857922 DOI: 10.1080/14712598.2022.2098674] [Reference Citation Analysis]
39 Antonarelli G, Giugliano F, Corti C, Repetto M, Tarantino P, Curigliano G. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel) 2021;14:884. [PMID: 34577584 DOI: 10.3390/ph14090884] [Reference Citation Analysis]
40 Wang S, Chen K, Lei Q, Ma P, Yuan AQ, Zhao Y, Jiang Y, Fang H, Xing S, Fang Y, Jiang N, Miao H, Zhang M, Sun S, Yu Z, Tao W, Zhu Q, Nie Y, Li N. The state of the art of bispecific antibodies for treating human malignancies. EMBO Mol Med 2021;13:e14291. [PMID: 34431224 DOI: 10.15252/emmm.202114291] [Reference Citation Analysis]
41 Khan S, Carvajal RD. Dual Immunological Checkpoint Blockade for Uveal Melanoma. J Clin Oncol 2021;39:554-6. [PMID: 33417487 DOI: 10.1200/JCO.20.03274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]